RxDoctor Payments Data

Nausheen Ali, MD

Nephrology · Anaheim, CANPI 1609869296

Payments from drug & device makers

$171,858in general payments, 2019–2025

Across 154 payments — averaging $1115.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$169K
  • AstraZeneca$764
  • Otsuka America Pharmaceutical, Inc.$420
  • Akebia Therapeutics Inc$247
  • Vifor Pharma, Inc.$182
  • Novartis$163
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$2,71798%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,858 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$255,544
Medicare patients
386
Services billed
1,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide16$47,650
FarxigaDapagliflozin Propanediol33$38,879
VeltassaPatiromer Calcium Sorbitex17$23,317
Sevelamer Carbonate92$21,472
LokelmaSodium Zirconium Cyclosilicate18$18,993
Sevelamer Hcl24$13,797
ProcritEpoetin Alfa12$8,728
Calcium Acetate75$4,696
RetacritEpoetin Alfa-Epbx11$4,481
Midodrine Hcl11$3,323
Cinacalcet Hcl12$2,479
ProsolParenteral Amino Acid 20% No.112$2,257
Losartan Potassium109$863
Furosemide145$794
Calcitriol105$737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$764$57,87251 claims
Fresenius USA Marketing, Inc.Velphoro$56$47,65016 claims
Johnson & JohnsonProcrit$122$8,72812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →